The Technical Analyst
Select Language :
Adaptimmune Therapeutics [ADAP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Adaptimmune Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Adaptimmune Therapeutics is listed at the  Exchange

3.95% $1.580

America/New_York / 27 mar 2024 @ 16:00


Adaptimmune Therapeutics: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 340.03 mill
EPS: -0.570
P/E: -2.77
Earnings Date: Mar 06, 2024
SharesOutstanding: 215.21 mill
Avg Daily Volume: 1.896 mill
RATING 2024-03-27
B
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -2.77 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.47x
Company: PE -2.77 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 1.410 - 1.750

( +/- 10.76%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-08 Ecor1 Capital, Llc Buy 0 Ordinary Shares
2024-03-18 Piccina Cintia Buy 5 088 864 Option to purchase Ordinary Shares
2024-03-18 Piccina Cintia Buy 1 130 832 Option to purchase Ordinary Shares
2024-01-17 Rawcliffe Adrian Sell 30 080 American Depositary Shares representing Ordinary Shares
2024-01-16 Rawcliffe Adrian Sell 9 304 American Depositary Shares representing Ordinary Shares
INSIDER POWER
96.18
Last 96 transactions
Buy: 71 750 188 | Sell: 1 254 319

Forecast: 16:00 - $1.570

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.570
Forecast 2: 16:00 - $1.570
Forecast 3: 16:00 - $1.570
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.580 (3.95% )
Volume 1.180 mill
Avg. Vol. 1.896 mill
% of Avg. Vol 62.25 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Adaptimmune Therapeutics PLC

Last 12 Months

Last 12 months chart data with high, low, open and close for Adaptimmune Therapeutics PLC

RSI

Intraday RSI14 chart for Adaptimmune Therapeutics PLC

Last 10 Buy & Sell Signals For ADAP

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:34sell$1.140N/AActive
Profile picture for
            Adaptimmune Therapeutics PLC

ADAP

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Last 10 Buy Signals

Date Signal @
OKBUSDMar 28 - 04:08$65.10
FLIPUSDMar 28 - 04:095.37
TBTCUSDMar 28 - 04:0369 857
STSOLUSDMar 28 - 04:04215.88
PROMUSDMar 28 - 04:04$14.33
AKH.OLMar 27 - 08:05NOK3.10
WOOUSDMar 28 - 04:04$0.463
SFPUSDMar 28 - 04:04$0.783
STRKUSDMar 28 - 04:04$13.95
POLYXUSDMar 28 - 04:040.604

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.